Skip to main content

Table 1 Patient, disease, and transplant characteristics

From: Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study

Characteristic (%)

MSD (n = 961)

UD (n = 593)

p value

Median follow-up, months

30 (1–157)

27 (1–137)

0.28

Median age, years (range)

49 (18–75)

52 (18–77)

<0.01

Median year of HSCT (range)

2006 (2000–2012)

2009 (2000–2012)

<0.01

Interval from diagnosis to HSCT, months (range)

8.6 (2–155)

10.3 (2.5–186)

<0.01

De novo AML

836 (87)

480 (81)

<0.01

sAML

125 (13)

113 (19)

 

Prior auto-HSCT

57 (6)

41 (7)

0.59

Donor’s gender

   

 Male

500 (52)

417 (72)

<0.01

 Female

452 (48)

162 (28)

 

CMV positive serostatus

  

<0.01

 Patient

472 (69)

210 (37)

 

 Donor

417 (62)

244 (42)

 

Conditioning regimen

   

 MAC

559 (60)

269 (46)

<0.01

 RIC

365 (40)

316 (54)

 

Conditioning details

   

 BuCy

155 (16)

81 (14)

<0.01

 BuFlu

135 (14)

112 (19)

 

 FluMel

89 (9)

81 (14)

 

 Threo-based

36 (4)

26 (4)

 

 MAC TBI

178 (1)

79 (13)

 

 RIC TBI

32 (3)

13 (2)

 

 Other

336 (35)

201 (34)

 

Stem cell source

   

 BM

107 (11)

60 (10)

0.14

 PBSC

854 (89)

533 (90)

 

GVHD prophylaxis

   

 CsA alone

115 (12)

81 (14)

<0.01

 CsA + MMF

182 (19)

187 (31)

 

 CsA + MTX

362 (38)

246 (41)

 

 Other

68 (7)

75 (13)

 

 Missing

234 (24)

4 (1)

 

In vivo TCD

  

<0.01

 ATG

167 (17)

388 (65)

 

 Alemtuzumab

20 (2)

47 (8)

 

 No

521 (54)

154 (26)

 

 Missing

235 (24)

4 (1)

 
  1. Abbreviations: MSD matched sibling donor, UD unrelated donor, HSCT hematopoietic stem cell transplantation, sAML secondary acute myeloid leukemia, auto-HSCT autologous stem cell transplantation, CMV cytomegalovirus, MAC myeloablative conditioning regimen, RIC reduced-intensity conditioning regimen, Bu busulfan, Cy cyclophosphamide, Flu fludarabine, Mel melphalan, Threo threosulfan, TBI total body irradiation, BM bone marrow, PBSC peripheral blood stem cells, CsA cyclosporine A, MMF mycophenolate mophetil, MTX methotrexate, TCD T-cell depletion, ATG antithymocyte globulin